Next Science Limited (NXS)
20mins delayed
Movement
1 Year Return
Next Science Limited Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $230.82 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
NXS Statistics
11 November
555 / 2,297
ASX Size Rank
1yr Return
vs Sector (1yr)
+24.25%
vs ASX 200 (1yr)
+46.38%
$230.82 million
Market Cap
Share Issue
106.37 million
All Ords (%)
N/A
Short Sold
0.04%
Current Fundamentals
11 November
N/A
PE Ratio
EPS ($)
-0.062
Earnings Yield
-2.84%
NTA ($)
0.18
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Next Science Limited (NXS) is a medical technology with a research and development centre in Florida, USA. NXS has four FDA cleared products currently available in the US market to treat and manage surgical site infections and chronic wounds. NXS owns 100% of the patent protected intellectual property relating to its Xbio technology. NXS products are as below:
Upcoming Calendar
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
NXS is not covered by a major broker.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr Mark Raymond Compton | Non-Executive Director | Oct 2018 |
|
| Mr George Savvides | Non-Executive Chairman, Non-Executive Director | Jul 2018 |
|
| Mr Bruce Alan Hancox | Non-Executive Director | Oct 2017 |
|
| Mr Dan Spira | Non-Executive Director | Oct 2017 |
|
| Mrs Aileen Stockburger | Non-Executive Director | Oct 2018 |
|
| Ms Judith Mitchell | Managing Director | Oct 2017 |
|
Director Transactions
NXS directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 25/09/19 | Dan Spira | Issued | 27,864 | $1.674 | $46,643 | Director remuneration. |
| 25/09/19 | Aileen Stockburger | Issued | 25,577 | $1.661 | $42,475 | Director remuneration. |
Shareholder Distribution
Shareholder Distribution data is unavailable.
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Auckland Trust Company Ltd |
46,507,500 | 25.96% |
| Walker Group Holdings Pty Ltd | 29,003,000 | 16.19% |
| Matthew Myntti | 20,657,000 | 11.53% |
| Christopher Samuel | 7,299,500 | 4.07% |
| James Mozley | 6,435,000 | 3.59% |
| Judith Mitchell | 4,732,000 | 2.64% |
| HSBC Custody Nominees (Australia) Limited | 4,579,167 | 2.56% |
| National Nominees Limited | 4,450,000 | 2.48% |
| UBS Nominees Pty Ltd | 2,000,000 | 1.12% |
| Charles Robert Dirck Wittenoom | 1,950,000 | 1.09% |
| Belgravia Strategic Equities Pty Ltd | 1,875,000 | 1.05% |
| J P Morgan Nominees Australia Pty Limited | 1,800,000 | 1.00% |
| Portfolio Services Pty Ltd | 1,781,000 | 0.99% |
| Scone Investments Pty Ltd | 1,781,000 | 0.99% |
| BNP Paribas Noms Pty Ltd |
1,600,000 | 0.89% |
| Citicorp Nominees Pty Limited | 1,544,000 | 0.86% |
| Merrill Lynch (Australia) Nominees Pty Limited | 1,500,000 | 0.84% |
| Byron Darroch | 1,170,000 | 0.65% |
| Michael Anderson | 1,124,500 | 0.63% |
| Aust Executor Trustees Ltd |
1,000,000 | 0.56% |
| All other shareholders | 20.31 % | |
The Top 20 Shareholders of NXS hold 79.69% of shares on issue.
NXS Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
NXS Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Commercialising and developing its Xbio technology, which is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria, in a range of products for the treatment of biofilm based infections.
Incorporated: --
Suite 1902, Level 19, Tower A The Zenith Building, 821 Pacific Hwy
Chatswood NSW 2067
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.